🇺🇸 FDA
Pipeline program

Palazestrant

OP-1250-003

Phase 1 small_molecule active

Quick answer

Palazestrant for Metastatic Breast Cancer is a Phase 1 program (small_molecule) at Olema Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Olema Pharmaceuticals
Indication
Metastatic Breast Cancer
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials